Lercaril (Enalapril Maleate, Lercanidipine Hydrochloride)

The enalapril component blocks the angiotensin‑converting enzyme, reducing angiotensin II levels and decreasing vasoconstriction. Lercanidipine blocks L‑type calcium channels in vascular smooth muscle, causing arterial dilation. Together, they lower peripheral resistance and help maintain normal blood‑pressure levels.

The specific dose of Lercaril is determined by the prescribing clinician based on the patient’s blood‑pressure readings, overall health status, and any concurrent medications. Dosage adjustments are made to achieve target blood‑pressure goals while minimizing side effects.

Safety of Lercaril in pregnancy or while breastfeeding has not been fully established. ACE inhibitors are generally avoided during the second and third trimesters because of potential fetal harm. Patients who are pregnant, planning pregnancy, or nursing should discuss alternatives with their healthcare provider.

To request Lercaril, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Unlike monotherapy agents, Lercaril delivers a fixed‑dose combination of an ACE inhibitor and a calcium‑channel blocker, offering broader blood‑pressure control through two mechanisms. This can improve efficacy and simplify regimens compared with taking two separate tablets, while maintaining a comparable safety profile.

Lercaril tablets should be stored at temperatures below 25 °C, in the original packaging, and protected from moisture and direct sunlight. Keeping the product in a dry, cool environment helps preserve its potency throughout its shelf life.

Lercaril is taken orally, usually once daily, with or without food as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless specifically advised by a healthcare professional.

Serious risks include angioedema, which can cause swelling of the face, lips, tongue or airway, and severe hypotension leading to dizziness or fainting. Patients should seek immediate medical attention if they experience rapid swelling, difficulty breathing, or a sudden drop in blood pressure.

Lercaril is contraindicated in individuals with a known hypersensitivity to enalapril, lercanidipine, or any component of the formulation. It should also be avoided in patients with a history of angioedema related to ACE‑inhibitor therapy and in those with severe renal or hepatic impairment unless specifically directed by a physician.